Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Visions of Harry Hill 
Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.
Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.
Denmark's Novo has a new insulin called Tresiba, or degludec, that is awaiting a U.S. approval decision by July 29 and could also get a green light in Europe in the second half of the year.
And Lilly's new long-acting insulin LY2605541, though still some years from reaching the market, is already causing a stir after signs in mid-stage Phase II clinical tests it may help patients lose weight.
http://uk.reuters.com/article/2012/05/29/us-sanofi-insulin-idUKBRE84S0J520120529
Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.
Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.
Denmark's Novo has a new insulin called Tresiba, or degludec, that is awaiting a U.S. approval decision by July 29 and could also get a green light in Europe in the second half of the year.
And Lilly's new long-acting insulin LY2605541, though still some years from reaching the market, is already causing a stir after signs in mid-stage Phase II clinical tests it may help patients lose weight.
http://uk.reuters.com/article/2012/05/29/us-sanofi-insulin-idUKBRE84S0J520120529